Varian Medical Systems stock stays delisted as parent Siemens Healthineers drives oncology growth

Published on 09/05/2026 at 22:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Varian Medical Systems stock is no longer traded independently after its acquisition by Siemens Healthineers, but the oncology specialist remains central to the parent group’s cancer care strategy and revenue mix.

VAR, US9229081089, Illustration mit AI erstellt.

Varian Medical Systems stock, historically listed under ISIN US9229081089, is no longer traded independently after the company’s acquisition and integration into Siemens Healthineers’ oncology business. As of September 5, 2026, investors access Varian’s exposure primarily through Siemens Healthineers shares, while Varian continues to play a key role in radiation oncology and cancer care technology within the group.

Varian’s role inside Siemens Healthineers

Following the takeover, Varian Medical Systems operates as the core of Siemens Healthineers’ oncology segment, contributing to the group’s portfolio of radiation therapy systems and software used worldwide in cancer treatment. The integration has allowed Siemens Healthineers to combine imaging, planning and treatment delivery into more comprehensive oncology workflows, making Varian’s former standalone business a central pillar of the wider group’s strategy.

For investors, the key figures relevant to Varian’s business now appear inside Siemens Healthineers’ reporting structure rather than in separate Varian Medical Systems filings. Group-level disclosures typically highlight revenue and margin contributions from oncology solutions, while historical Varian numbers prior to the acquisition serve only as background and are no longer updated as standalone fundamentals. Historical: before the acquisition, Varian reported significant annual revenue from radiation oncology systems and services, but those figures are now subsumed into Siemens Healthineers’ consolidated accounts.

Oncology market dynamics and scale

The oncology equipment and services market in which Varian operates continues to grow, driven by rising cancer incidence, advances in precision radiotherapy and expanding access to treatment in emerging markets. Market research and industry reporting regularly point to multi-billion dollar global spending on radiation therapy equipment and related software, with Varian and a small number of peers supplying a substantial share of installed systems in hospitals and cancer centers.

In this environment, Siemens Healthineers’ oncology segment, built around Varian technologies, competes on the basis of treatment accuracy, workflow integration and long-term service contracts. Historically, Varian’s business model combined sales of linear accelerators and treatment planning systems with recurring revenue from software licenses, maintenance, and upgrade services, leading to a mix of upfront and recurring cash flows that has now been consolidated within Siemens Healthineers’ reporting.

Representative product: TrueBeam system

One representative product from Varian’s portfolio is the TrueBeam radiation therapy system, which is designed to deliver high-precision doses of radiation to cancerous tissue while sparing as much healthy tissue as possible. The system supports advanced treatment techniques such as intensity-modulated radiotherapy and stereotactic radiosurgery, and is deployed in hospitals and dedicated cancer centers worldwide as part of comprehensive oncology programs.

Stock access via Siemens Healthineers

Because Varian Medical Systems stock itself is no longer listed, investors seeking exposure to Varian’s radiation oncology business typically do so by holding Siemens Healthineers shares, which reflect the integrated performance of imaging, diagnostics and oncology, including the Varian portfolio. For these investors, current market figures such as share price, market capitalization and index membership relate to Siemens Healthineers rather than to the former Varian Medical Systems listing.